Table 8 Publications investigating EVs from cells not fitting in the previously described categories.

From: Evaluation of the cardioprotective potential of extracellular vesicles – a systematic review and meta-analysis

Ref.

Source

PM

Size

Injury model

Main effector

EV marker

Y. Wang et al.45

Induced pluripotent stem cells

Precipitation

100 nm

I/R-injury

(miR-21, miR-210)

CD63, TSG101

T. Kang et al.14

Adipose-derived stem cells

UC

<1 µm

NSI

miR-31

Alix

Gu et al.19

Endothelial progenitor cells

UC

NSI

Angiotensin II-Induced hypertrophy

NSI

NSI

Vandergriff et al.51

Cardiac stem cells

Ultrafiltration

129.6 nm

doxorubicin induced cardiomyopathy

NSI

CD63

Ong et al.38

Endothelial cells

Precipitation

30–110 nm

Hypoxic stress in vitro

miR-126, miR-210

CD63, CD9

Balbi et al.26

Human amniotic fluid stem cells

UC

50–200 nm

Muscle atrophy, H2O2

NSI

TSG101, Alix, CD81, CD9, CD63, Annexin V

Davidson et al.27

HUVECs

UC

≈100 nm

Hypoxia reoxygenation

NSI

CD81

Obata et al.29

Endothelial F2 cells

UC, density gradient,

≈90 nm*

NSI

NSI

Alix, HSP70, CD63 syntenin

  1. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated. UC = ultracentrifugation; I/R = ischemia/reperfusion; NSI = not specifically indicated; Ref. = reference; TSG = tumour susceptibility gene; HSP = heat shock protein; *self-assessed (assumption made from nanoparticle tracking analysis).
Back to article page